Company Overview and News

 
NOMD vs. MGPI: Which Stock Should Value Investors Buy Now?

2018-08-28 zacks
Investors interested in stocks from the Food - Miscellaneous sector have probably already heard of Nomad Foods (NOMD - Free Report) and MGP (MGPI - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
NOMD BGSF

 
Nomad Foods Ltd. (NOMD) CEO Stéfan Descheemaeker on Q2 2018 Results - Earnings Call Transcript

2018-08-13 seekingalpha
Nomad Foods Ltd. (NYSE:NOMD) Q2 2018 Results Earnings Conference Call August 9, 2018 8:30 AM ET
NOMD

1
Young's Seafood in three-way battle over £200m sale

2018-08-12 telegraph.co.uk - 1
Young's Seafood has become the subject of a three-way bid battle as a potential £200m sale of the frozen food manufacturer nears conclusion.
NOMD

 
Nomad Foods Ltd. 2018 Q2 - Results - Earnings Call Slides

2018-08-10 seekingalpha
The following slide deck was published by Nomad Foods Ltd. in conjunction with their 2018 Q2 earnings call.
NOMD

2
Nomad Foods (NOMD) Q2 Earnings and Revenues Surpass Estimates

2018-08-09 zacks
Nomad Foods (NOMD - Free Report) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.
HCCDZ HCHC GWRS UCTI NOMD SND RLH UCTT

6
Buy Nomad Foods For 25% Upside

2018-08-06 seekingalpha
Packaged food stocks have fallen out of favor with investors because of stagnant revenue growth and bland profit margins. A shift towards healthier food options and heightened competition from private label and niche brands have wiped off over 4.4% market value of food sector over the past one year, with big players like Kraft Heinz (KHC) and General Mills (GIS) losing as much as 25.6% and 14.4%, respectively.
GIS KHC NOMD

66
Top Analyst Upgrades and Downgrades: Applied Materials, BioCryst, Costco, Generac, Goodyear, Intel, Microsoft, Netflix and More

2018-07-17 247wallst - 3
Stocks were marginally lower on Tuesday after investors took a bite out of the FANG stocks. Investors have had less faith and lower rewards by buying the dips in 2018 than in prior years. Many of those investors also have been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and also for the longer term.
WFCNP LRCX PM DB DRI NFLX NOMD ILMN KLAC CRL SHW AMT GNRC AMAT MS INTC BLDR WFC COST BCRX ARW INNT TRI MSFT

 
NOMD / Nomad Foods Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-07-02 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NOMD

2
Conagra Brands & Pinnacle Foods Deal Talks Back in Focus

2018-06-22 zacks
There was a lot of hearsay about Conagra Brands, Inc. (CAG - Free Report) trying to strike a deal to buy Pinnacle Foods Inc. (PF - Free Report) , which sent shares of the latter up by 2.3% in yesterday’s trading session. If the consolidation materializes, it is likely to create a robust frozen foods entity at a time when demand for this category is booming. However, both Conagra and Pinnacle Foods have remained silent on the matter.
LW PF NOMD

 
Italian pasta maker appoints former Nomad Foods exec as CEO ahead of listing

2018-06-18 reuters
MILAN, June 18 (Reuters) - Italy’s De Cecco said on Monday it had appointed a former Nomad Foods top manager as its new chief executive, the first non-family member to lead the pasta maker as the group sets out for a market listing.
NOMD

 
NOMD / Nomad Foods Ltd. / FRANKLIN MARTIN E - SC 13D/A (Activist Investment)

2018-06-15 sec.gov
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NOMD

2
NOMD / Nomad Foods Ltd. / FRANKLIN MARTIN E - SC 13D/A (Activist Investment)

2018-06-15 sec.gov - 2
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NOMD

46
4 Food Stocks Ready for Growth as Tastes Change | InvestorPlace

2018-06-11 investorplace
Most of the larger food stocks find themselves in a secular decline. Packaged foods from the likes of Kellogg Company (NYSE:K), General Mills, Inc. (NYSE:GIS) and Kraft Heinz Co (NYSE:KHC) have become less popular. As a result, these companies have experienced secular revenue declines despite growing populations.
GIS YUM MKC COST KHC NOMD K PPC WMT UNFI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: G6564A105